Zhao Yan, Sun Xin, He Yun, Tang Zhirong, Peng Guoping, Liu Aiwen, Qiao Xiaochun, Li Huiqin, Chen Zhiqiang, Dou Zhihui, Ma Ye, Liu Zhongfu, Zhang Fujie
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, Xuan Wu District, China.
AIDS Care. 2010 Oct;22(10):1182-8. doi: 10.1080/09540121003615129.
In 2003, the Chinese Government initiated a free antiretroviral therapy (ART) program focusing on adult AIDS patients. Pediatric antiretroviral (ARV) formulations were yet unavailable. It was not until July 2005, with the initiation of a two-stage program implemented by the Chinese Ministry of Health, that pediatric formulations became accessible in China. Initially, the pediatric ART program was piloted in six provinces with the highest incidences of pediatric HIV/AIDS. The pilot stage allowed the Chinese Center for Disease Control and Prevention (CCDC) to finalize entry criteria, treatment regimen, and patient monitoring and follow-up procedures. The second stage commenced at the end of 2006 when the program was scaled-up nationally. In order to guarantee treatment of pediatric patients, extensive training in the selection of appropriate ARV drug regimen and dosage was provided to doctors, often through on-site collaboration with domestic and international experts. The CCDC simultaneously established a pediatric ARV management system and a pediatric ART information system. CD4 count and other laboratory tests are being routinely performed on these pediatric patients. By the end of June 2009, 1529 pediatric patients had received ARV under the national program. However, challenges remain. Firstly, many children infected with HIV/AIDS live in rural areas where the treatment quality is hindered by the limited number of medical facilities and skilled medical workers. Secondly, much of the pediatric ARV drug supply depends on donation. An effort needs to be made by the Chinese Government to establish China's own drug procurement and supply system.
2003年，中国政府启动了一项针对成年艾滋病患者的免费抗逆转录病毒疗法（ART）项目。当时尚无儿科抗逆转录病毒（ARV）制剂。直到2005年7月，随着中国卫生部实施两阶段项目，儿科制剂才在中国可供使用。最初，儿科ART项目在儿科艾滋病毒/艾滋病发病率最高的六个省份进行试点。试点阶段使中国疾病预防控制中心（CCDC）能够确定入组标准、治疗方案以及患者监测和随访程序。第二阶段于2006年底开始，当时该项目在全国范围内扩大规模。为了确保儿科患者得到治疗，通常通过与国内外专家的现场合作，为医生提供了关于选择合适的抗逆转录病毒药物方案和剂量的广泛培训。中国疾病预防控制中心同时建立了儿科抗逆转录病毒管理系统和儿科ART信息系统。这些儿科患者定期进行CD4计数和其他实验室检查。到2009年6月底，有1529名儿科患者在国家项目下接受了抗逆转录病毒治疗。然而，挑战依然存在。首先，许多感染艾滋病毒/艾滋病的儿童生活在农村地区，那里的医疗设施数量有限和熟练医疗工作者匮乏阻碍了治疗质量。其次，儿科抗逆转录病毒药物的供应很大程度上依赖捐赠。中国政府需要努力建立自己的药品采购和供应系统。
